Clinical review report. indication: treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Certolizumab pegol (Cimzia) (UCB Canada Inc.) :
The objective of this report was to perform a systematic review of the beneficial and harmful effects of Certolizumab pegol 400 mg and 200 mg every two weeks administered as an subcutaneous injection for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for...
Saved in:
| Online Access: |
Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
CADTH,
2020
|
| Edition: | Final (with redactions). |
| Series: | Common drug review clinical review report.
|
| Subjects: |
| Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of Certolizumab pegol 400 mg and 200 mg every two weeks administered as an subcutaneous injection for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. |
|---|---|
| Physical Description: | 1 online resource (1 PDF file (120 pages)) : illustrations. |
| Bibliography: | Includes bibliographical references. |
| Source of Description, Etc. Note: | Description based on online resource; title from PDF title page (viewed March 15, 2021). |
| Funding Information Note: | Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec. |
